epigallocatechin gallate has been researched along with 2019 Novel Coronavirus Disease in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 16 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X | 1 |
| Bimonte, S; Cascella, M; Cuomo, A; Cuomo, M; Esposito, G; Forte, CA | 1 |
| Chattree, V; Goel, A; Lone, A; Maity, A; Singh, K | 1 |
| Baig, MS; Hara, Y; Hishiki, T; Ohishi, T; Rajpoot, S; Saqib, U; Takasaki, T | 1 |
| Bertoldi, M; Campagnari, R; Crupi, R; Cuzzocrea, S; Di Paola, R; Menegazzi, M | 1 |
| Banerjee, A; Maiti, S | 1 |
| Grebenchikov, OA; Zinovkin, RA | 1 |
| Eiser, AR | 1 |
| Chen, JC; Chen, YT; Chiou, WC; Huang, C; Hwang, LH; Lyu, YS; Yang, HY; Yang, JM | 1 |
| Alsaadawe, M; Chen, X; Chen, Z; Disoma, C; Dong, Z; Du, A; Hu, L; Jiang, T; Li, S; Liu, P; Liu, S; Mo, L; Peng, J; Peng, Y; Razzaq, A; Shen, Y; Xia, Z; Yang, Q; Zhang, Q; Zhang, Y; Zheng, R; Zhou, Y | 1 |
| Battu, A; Chourasia, M; Koppula, PR; Ouseph, MM; Singh, AK | 1 |
| Auste, A; Henss, L; Mühlebach, MD; Schmidt, C; Schnierle, BS; Schürmann, C; von Rhein, C | 1 |
| Bellanti, JA; Boner, AL; Concia, E; Girotto, S; Piazza, M | 1 |
| Ha, NC; Hong, S; Kwon, Y; Seo, SH; Song, M; Woo, SJ | 1 |
| Das, VRA; Joseph, J; Karthika, T; Raj, VS | 1 |
| Ichitani, M; Kawamoto, M; Kinugasa, H; Kobayashi, M; Mazda, O; Ohgitani, E; Shin-Ya, M; Takihara, T | 1 |
5 review(s) available for epigallocatechin gallate and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries | 2020 |
An Overview on the Potential Roles of EGCG in the Treatment of COVID-19 Infection.
Topics: Antiviral Agents; Catechin; COVID-19; COVID-19 Drug Treatment; Humans; Tea | 2021 |
A comprehensive review on modulation of SIRT1 signaling pathways in the immune system of COVID-19 patients by phytotherapeutic melatonin and epigallocatechin-3-gallate.
Topics: Antioxidants; Antiviral Agents; COVID-19; Humans; Immune System; Inflammation; Melatonin; SARS-CoV-2; Signal Transduction; Sirtuin 1 | 2022 |
Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Topics: Anti-Inflammatory Agents; Antioxidants; Autoimmune Diseases; Betacoronavirus; Catechin; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Humans; NF-kappa B; Pandemics; Plant Extracts; Pneumonia, Viral; Pulmonary Fibrosis; SARS-CoV-2; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor | 2020 |
EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection.
Topics: Antiviral Agents; Binding Sites; Catechin; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Cysteine Proteinase Inhibitors; Humans; SARS-CoV-2; Tea | 2021 |
11 other study(ies) available for epigallocatechin gallate and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
Topics: Angiotensin-Converting Enzyme 2; Caco-2 Cells; Catechin; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Docking Simulation; Peptidyl-Dipeptidase A; Protein Binding; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |
Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.
Topics: Angiotensin-Converting Enzyme 2; Biflavonoids; Binding Sites; Catechin; Computational Biology; COVID-19; Gallic Acid; Humans; Hydroxychloroquine; Molecular Docking Simulation; Protein Structure, Secondary; Protein Structure, Tertiary; Spike Glycoprotein, Coronavirus; X-Ray Diffraction | 2021 |
Transcription Factor Nrf2 as a Potential Therapeutic Target for Prevention of Cytokine Storm in COVID-19 Patients.
Topics: Animals; Antioxidants; Betacoronavirus; Catechin; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Dimethyl Fumarate; Female; Humans; Immunosuppressive Agents; Inflammation; Isothiocyanates; Male; Mice; Molecular Targeted Therapy; NF-E2-Related Factor 2; Oxidative Stress; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; Resveratrol; SARS-CoV-2; Signal Transduction; Sulfoxides; Thiosulfates | 2020 |
Could Dietary Factors Reduce COVID-19 Mortality Rates? Moderating the Inflammatory State.
Topics: Catechin; COVID-19; Curcumin; Cytokines; Diet; Humans; Inflammation; Linoleic Acid; Nutritional Physiological Phenomena | 2021 |
The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Topics: Binding Sites; Catechin; Coronavirus 3C Proteases; COVID-19; Drug Evaluation, Preclinical; Humans; Hydrolyzable Tannins; Kinetics; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Pandemics; Protease Inhibitors; Protein Binding; Protein Domains; SARS-CoV-2; Virus Replication | 2022 |
Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
Topics: Adult; Antiviral Agents; Catechin; China; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Female; Fluorescence Resonance Energy Transfer; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Docking Simulation; Pandemics; Protease Inhibitors; Retrospective Studies; SARS-CoV-2; Virus Replication; Young Adult | 2021 |
The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
Topics: Animals; Antiviral Agents; Betacoronavirus; Catechin; Cell Survival; Chlorocebus aethiops; COVID-19; HEK293 Cells; Humans; Lentivirus; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tea; Vero Cells; Virus Attachment; Virus Replication | 2021 |
Is nutraceutical supplementation appropriate for COVID-19 management?
Topics: Berberine; Catechin; COVID-19; Curcumin; Dietary Supplements; Humans; Lactobacillus; NF-E2-Related Factor 2; Receptor, Angiotensin, Type 1; SARS-CoV-2 | 2021 |
Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain.
Topics: Antiviral Agents; Catechin; COVID-19; Endoribonucleases; Humans; Pandemics; SARS-CoV-2; Uridylate-Specific Endoribonucleases; Viral Nonstructural Proteins | 2021 |
Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses.
Topics: Catechin; COVID-19; Humans; Middle East Respiratory Syndrome Coronavirus; SARS-CoV-2 | 2021 |
Significant Inactivation of SARS-CoV-2 In Vitro by a Green Tea Catechin, a Catechin-Derivative, and Black Tea Galloylated Theaflavins.
Topics: Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Biflavonoids; Catechin; Cell Survival; Chlorocebus aethiops; COVID-19; Gallic Acid; Humans; Protein Interaction Maps; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tea; Vero Cells; Virus Replication | 2021 |